-
公开(公告)号:US20170114075A1
公开(公告)日:2017-04-27
申请号:US15253369
申请日:2016-08-31
Applicant: Xenon Pharmaceuticals Inc.
Inventor: Mikhail Chafeev , Sultan Chowdhury , Lauren Fraser , Jianmin Fu , Jonathan Langille , Shifeng Liu , Jianyu Sun , Shaoyi Sun , Serguei Sviridov , Mark Wood , Alla Yurevna Zenova , Qi Jia , Jean-Jacques Alexandre Cadieux , Simon J. Gauthier , Amy Frances Douglas , Tom Hsieh , Nagasree Chakka , Zoran Cikojevic
IPC: C07D513/22 , C07D491/20 , C07D495/20 , C07D498/20 , C07D491/22 , C07D513/20 , C07D491/107
CPC classification number: C07D513/22 , C07D491/10 , C07D491/107 , C07D491/20 , C07D491/22 , C07D495/20 , C07D498/20 , C07D513/20 , C07D519/00
Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
-
公开(公告)号:US09630929B2
公开(公告)日:2017-04-25
申请号:US14355552
申请日:2012-10-30
Applicant: XENON PHARMACEUTICALS INC.
Inventor: Shaoyi Sun , Alla Yurevna Zenova , Mikhail Chafeev , Qi Jia , Zaihui Zhang , Renata Marcella Oballa
IPC: C07D417/12 , C07D239/42 , C07D285/08 , C07D401/12 , C07D413/12 , C07D211/22 , C07D257/06 , C07D261/14 , C07D277/52 , C07D285/135
CPC classification number: C07D239/42 , C07D211/22 , C07D257/06 , C07D261/14 , C07D277/52 , C07D285/08 , C07D285/135 , C07D401/12 , C07D413/12 , C07D417/12
Abstract: This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.
-
33.
公开(公告)号:US20170002017A1
公开(公告)日:2017-01-05
申请号:US15017282
申请日:2016-02-05
Applicant: GENENTECH, INC. , XENON PHARMACEUTICALS INC.
Inventor: Jean-Christophe Andrez , Sultan Chowdhury , Shannon Marie Decker , Christoph Martin Dehnhardt , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Qi Jia , Jun Li , Daniel F. Ortwine , Brian Safina , Tao Sheng , Shaoyi Sun , Daniel P. Sutherlin , Michael Scott Wilson , Alla Yurevna Zenova
IPC: C07D491/107 , C07C311/51 , C07D307/12 , C07D213/82 , C07D205/04 , C07D207/48 , C07D295/26 , C07D257/04 , C07D311/58 , C07D209/52 , C07D307/18 , C07D211/22 , C07D233/84
CPC classification number: C07D491/107 , A61K31/18 , A61K31/397 , A61K31/40 , A61K31/41 , A61K31/4164 , A61K31/44 , A61K31/5375 , C07B2200/05 , C07C307/06 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/10 , C07C2602/18 , C07C2602/20 , C07C2602/42 , C07C2602/44 , C07C2602/50 , C07C2603/66 , C07C2603/68 , C07C2603/74 , C07D205/04 , C07D207/46 , C07D207/48 , C07D209/52 , C07D211/22 , C07D211/96 , C07D213/64 , C07D213/82 , C07D233/84 , C07D257/04 , C07D265/30 , C07D295/192 , C07D295/26 , C07D307/12 , C07D307/18 , C07D309/08 , C07D311/58 , C07D311/70 , C07D311/72 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02 , C07D471/08
Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Abstract translation: 和其药学上可接受的盐,其中变量RA,下标n,环A,X2,L,下标m,X1,B,R1,R2,R3,R4,R5和RN具有本文所述的含义, 化合物和使用这些化合物和组合物的方法。
-
公开(公告)号:US20160297754A1
公开(公告)日:2016-10-13
申请号:US15133030
申请日:2016-04-19
Applicant: GENENTECH, INC. , XENON PHARMACEUTICALS INC.
Inventor: Sultan Chowdhury , Christoph Martin Dehnhardt , Thilo Focken , Michael Edward Grimwood , Ivan William Hemeon , Qi Jia , Daniel Ortwine , Brian Safina , Shaoyi Sun , Daniel P. Sutherlin , Alla Yurevna Zenova
IPC: C07C311/51 , C07D213/82 , C07D213/64 , C07D205/04 , C07D471/08 , C07D405/12 , C07D295/26 , C07D233/84 , C07D257/04 , C07D207/46 , C07C307/06 , C07D311/58
CPC classification number: C07D491/107 , A61K31/18 , A61K31/397 , A61K31/40 , A61K31/41 , A61K31/4164 , A61K31/44 , A61K31/5375 , C07B2200/05 , C07C307/06 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/10 , C07C2602/18 , C07C2602/20 , C07C2602/42 , C07C2602/44 , C07C2602/50 , C07C2603/66 , C07C2603/68 , C07C2603/74 , C07D205/04 , C07D207/46 , C07D207/48 , C07D209/52 , C07D211/22 , C07D211/96 , C07D213/64 , C07D213/82 , C07D233/84 , C07D257/04 , C07D265/30 , C07D295/192 , C07D295/26 , C07D307/12 , C07D307/18 , C07D309/08 , C07D311/58 , C07D311/70 , C07D311/72 , C07D403/12 , C07D405/12 , C07D413/12 , C07D451/02 , C07D471/08
Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Abstract translation: 和其药学上可接受的盐,其中变量RA,下标n,环A,X2,L,下标m,X1,B,R1,R2,R3,R4,R5和RN具有本文所述的含义, 化合物和使用这些化合物和组合物的方法。
-
-
-